Jul
26
Horizon Pharma, Inc. Announces Results Of Phase 3 Study Of LODOTRA� Demonstrate 12-Month Sustained Efficacy And Safety …
Filed Under (Main Content) by Content Keyword RSS
Horizon Pharma, Inc. announced today the results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) Phase 3 European registration study of LODOTRA, a programmed release formulation of low-dose prednisone, which showed sustained improvement in reducing the duration of morning stiffness in patients with Rheumatoid Arthritis (RA ...
Jul
14
Arthritis Foundation launches screening program
Filed Under (Main Content) by Content Keyword RSS
The Arthritis Foundation has begun a new pilot program designed to improve the early diagnosis of rheumatoid arthritis (RA).
Jul
13
Arthritis Foundation launches screening program
Filed Under (Main Content) by Content Keyword RSS
The Arthritis Foundation has begun a new pilot program designed to improve the early diagnosis of rheumatoid arthritis (RA).
Jul
12
Arthritis Foundation launches screening program
Filed Under (Main Content) by Content Keyword RSS
The Arthritis Foundation has begun a new pilot program designed to improve the early diagnosis of rheumatoid arthritis (RA).
Jul
11
Arthritis Foundation launches screening program
Filed Under (Main Content) by Content Keyword RSS
The Arthritis Foundation has begun a new pilot program designed to improve the early diagnosis of rheumatoid arthritis (RA).